Table 2. Studies included in Phase I Analysis grouped by Intervention.
| ACEi and/or ARB vs Placebo (N = 32557) | ACEi vs ACEi plus ARB |
| • Hope 2000 | • ONTARGET 2008 |
| • DIABHYCAR 2004 | ACEi vs Beta Blocker (N = 100) |
| • AIPRI 1996 | • Hannedouche T, et al 1994 |
| • CSG 1993 | ACEi vs CCB (N = 1274) |
| • Ruggenenti 1999 | • AASK 2001 |
| • ATLANTIS 2000 | • DIAL 2004 |
| • Laffel L, et al 1995 | ACEi vs Diuretic (N = 33927) |
| • MCSG 1996 | • NESTOR 2004 |
| • REIN 1997 | • ALLHAT_BP 2005 |
| • TRANSCEND 2009 | Allopurinol vs Control (N = 113) |
| • DIRECT 2009 | • Goicoechea M, et al 2010 |
| • RENAAL 2001 | Bardoxolone vs Placebo (N = 227) |
| • ROADMAP 2011 | • BEAM 2011 |
| • IRMA2 2001 | CCB vs Placebo (N = 2352) |
| • Val-HeFT 2009 | • BENEDICT 2004 |
| • Mauer M, et al 2009 | CCB vs Diuretic (N = 33357) |
| • BENEDICT 2004 | • ALLHAT_BP 2005 |
| • IDNT 2001 | |
| Intensive vs Conventional Glycemic Control (N = 29353)¥ | Conventional therapy vs Conventional plus AST-120 therapy for CKD (N = 479) |
| • UKPDS34 1998 | • CAP-KD 2009 |
| • UKPDS33 1998 | CCB vs ARB (N = 5851) |
| • DCCT 1993 | • CASE-J 2008 |
| • Kumamoto 1995 | • IDNT 2001 |
| • VADT 2009 | Intensive vs Conventional BP Control (N = 335) |
| • ADVANCE 2008 | • REIN 2 2005 |
| • ACCORD 2010 | Ibopamine vs Control (N = 189) |
| Usual vs Structured Care of CKD (N = 506) * | • Stefoni S, et al 1996 |
| • Rachmani R, et al 2004 | Statin vs Placebo (N = 18896) * |
| • Steno Type 2 1999 | • 4S |
| • SURE 2009 | • AFCAPS-TexCAPS 2010 |
| ACEi plus CCB vs ACEi (N = 509) | • ALLHAT_LIPID 2008 |
| • BENEDICT-B 2011 | Statin plus Ezetimibe vs Placebo (N = 9270) |
| • Fogari R, et al 2002 | • SHARP 2011 |
| ACEi plus CCB vs Placebo (N = 1204) | Pimagedline (AGE Inhibitor) vs Placebo (N = 690) |
| • BENEDICT 2004 | • ACTION I 2004 |
| ACEi plus CCB vs ACEi plus Diuretic (N = 11810) | CR-LIPE Diet vs Control (N = 191) |
| • ACCOMPLISH 2010 | • Facchini F, et al 2003 |
| • GUARD 2008 | Vitamin B vs Placebo (N = 252) |
| ACEi plus CCB vs CCB (N = 309) | • DIVINe 2010 |
| • Fogari R, et al 2002 | |
| ACEi plus Diuretics vs Placebo (N = 11140) | |
| • ADVANCE 2007 |
¥
Micro and macroalbuminuria were the only renal outcomes improved by intervention. No beneficial effect of intervention reported for other renal outcomes (doubling of creatinine, ESRD), thus not forwarded to phase II analysis.
*
No beneficial effects seen for renal outcomes by this intervention thus not forwarded to phase II analysis.
ACEi Angiotensin converting enzyme inhibitor; ARB Angiotensin receptor blocker; CCB Calcium channel blocker; AST-120 an oral adsorbent agent; AGE Advanced glycation endproduct; CR-LIPE carbohydrate restricted low iron available polyphenol enriched diet.